InsiderSignal.AI

InsiderSignal.ai

RLAY - Relay Therapeutics, Inc.

Insider Sale by Catinazzo Thomas (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Catinazzo Thomas, serving as CFO at Relay Therapeutics, Inc. (RLAY), sold 19,517 shares at $13.19 per share, for a total transaction value of $257,498.00. Following this transaction, Catinazzo Thomas now holds 213,867 shares of RLAY.

This sale represents a 8.00% decrease in Catinazzo Thomas's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, April 7, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 9, 2026, 2 days after the trade was made.

Relay Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Catinazzo Thomas

CFO

Thomas Catinazzo is the Chief Financial Officer of Relay Therapeutics, a clinical-stage precision medicine company focused on discovering transformative drugs through innovative protein motion technology[[1]](https://relaytx.com/our-team/tom-catinazzo/)[[3]](https://www.zoominfo.com/p/Thomas-Catinazzo/1540817215). He has served in this role since January 2022, having previously held positions as Senior Vice President of Finance (August 2020–January 2022) and Vice President of Finance (April 2018–August 2020) at Relay[[2]](https://fintool.com/app/research/companies/RLAY/people/thomas-catinazzo). Prior to joining Relay, Catinazzo spent approximately five years at Foundation Medicine, where he served as Vice President of Financial Planning & Analysis and Senior Director of Financial Planning & Analysis, overseeing critical business planning functions[[2]](https://fintool.com/app/research/companies/RLAY/people/thomas-catinazzo)[[3]](https://www.zoominfo.com/p/Thomas-Catinazzo/1540817215). His extensive biotechnology finance background, spanning more than 12 years, also includes experience at Aileron Therapeutics and Genzyme Corporation in various business unit finance roles[[1]](https://relaytx.com/our-team/tom-catinazzo/). Catinazzo holds a Bachelor of Science in Finance from Boston College[[1]](https://relaytx.com/our-team/tom-catinazzo/)[[2]](https://fintool.com/app/research/companies/RLAY/people/thomas-catinazzo). As CFO, he oversees comprehensive financial operations including financial planning and analysis, accounting, tax, procurement, treasury, and information technology functions[[1]](https://relaytx.com/our-team/tom-catinazzo/). As of March 2026, he directly owns 231,584 shares of Relay Therapeutics common stock, demonstrating substantial ongoing equity interest in the company[[5]](https://www.gurufocus.com/news/8699962/insider-sell-thomas-catinazzo-sells-shares-of-relay-therapeutics-inc-rlay)[[6]](https://www.stocktitan.net/sec-filings/RLAY/form-4-relay-therapeutics-inc-insider-trading-activity-9c16903e594f.html).

View full insider profile →

Trade Price

$13.19

Quantity

19,517

Total Value

$257,498.00

Shares Owned

213,867

Trade Date

Tuesday, April 7, 2026

8 days ago

SEC Filing Date

Thursday, April 9, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Relay Therapeutics, Inc.

Company Overview

No company information available
View news mentioning RLAY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5609227

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime